Alex Mutebi

Genmab (United States) — United States

Medicine · Health Sciences

16h-index862citations87works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(23), Chronic Lymphocytic Leukemia Research(13), CAR-T cell therapy research(13), Southeast Asian Sociopolitical Studies(12), Lung Cancer Treatments and Mutations(10)

Publications87 total

Effectiveness of epcoritamab in a heterogeneous population with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) including post-chimeric antigen receptor T-cell therapy (CAR T) patients: Insights from the real-world epcoritamab patient characteristics and outcomes research (Real-EPCOR) study
Blood·2025
Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US
Future Oncology·2025Open Access
THE EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS STANDARD OF CARE (SCHOLAR-5) IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AFTER ≥2 SYSTEMIC THERAPIES: AN INDIRECT TREATMENT COMPARISON
Hematology Transfusion and Cell Therapy·2025Open Access
Indirect Comparison of Epcoritamab Versus Axicabtagene Ciloleucel in Chimeric Antigen Receptor T-Cell–Eligible and –Naive Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Clinical Lymphoma Myeloma & Leukemia·2025· 1 citedOpen Access
578 | PATTERNS OF CHEMOIMMUNOTHERAPY USE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA IN THE US COMMUNITY SETTING
Hematological Oncology·2025Open Access
241 | MATCHING‐ADJUSTED INDIRECT COMPARISON OF EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE VERSUS TAFASITAMAB WITH RITUXIMAB + LENALIDOMIDE IN SECOND‐LINE + FOLLICULAR LYMPHOMA
Hematological Oncology·2025Open Access
248 | MATCHING‐ADJUSTED INDIRECT COMPARISON OF EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE VERSUS LISOCABTAGENE MARALEUCEL IN SECOND‐LINE FOLLICULAR LYMPHOMA
Hematological Oncology·2025Open Access
291 | MATCH‐ADJUSTED COMPARISON OF EPCORITAMAB VERSUS NON‐ANTHRACYCLINE CHEMOIMMUNOTHERAPY IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS WITH HIGH CARDIOVASCULAR RISK
Hematological Oncology·2025Open Access
659 | TREATMENT OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS WITH HIGH CARDIOVASCULAR RISK AND TREATED WITH NON‐ANTHRACYCLINE–CONTAINING REGIMENS
Hematological Oncology·2025Open Access
572 | PATIENT‐REPORTED OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA PATIENTS TREATED WITH EPCORITAMAB: OVERALL AND SUBGROUP ANALYSIS BY BASELINE SYMPTOM BURDEN
Hematological Oncology·2025Open Access
663 | PATIENT PREFERENCES FOR ATTRIBUTES OF BISPECIFIC ANTIBODIES INDICATED FOR THE TREATMENT OF RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA IN THE UNITED STATES
Hematological Oncology·2025Open Access
292 | MATCH‐ADJUSTED COMPARATIVE ANALYSIS OF THE EFFICACY OF EPCORITAMAB + R‐miniCHOP VERSUS R‐miniCHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA
Hematological Oncology·2025Open Access
238 | EPCORITAMAB PLUS LENALIDOMIDE AND RITUXIMAB ACHIEVES HIGH RESPONSE RATES AND SURVIVAL BENEFITS COMPARED WITH USUAL CARE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Hematological Oncology·2025Open Access
325 | MATCH‐ADJUSTED COMPARATIVE ANALYSIS OF EPCORITAMAB + R‐DHAX/C OR R‐ICE VERSUS R‐DHAX/C OR R‐ICE IN 2L+ TRANSPLANT‐ELIGIBLE PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA
Hematological Oncology·2025Open Access
MO20-6 Real-world treatment patterns and outcomes in Japanese patients with large B-cell lymphoma after two systemic therapies
Annals of Oncology·2024
Logistical challenges of CAR T-cell therapy in non-Hodgkin lymphoma: a survey of healthcare professionals
Future Oncology·2024· 6 citedOpen Access
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma
Journal of Hematology & Oncology·2024· 8 citedOpen Access
Efficacy of Subcutaneous Epcoritamab Vs Tisa-Cel in R/R LBCL CAR T-Naive and CAR T-Eligible Patients: An Indirect Comparison
Blood·2023· 1 citedOpen Access
P1154: EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS AXI-CEL IN R/R DLBCL CAR T-NAIVE AND CAR T-ELIGIBLE PATIENTS: AN INDIRECT COMPARISON
HemaSphere·2023· 3 citedOpen Access
P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS
HemaSphere·2023· 1 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Bradley S. Stolshek(7), Anand A. Dalal(6), Annie Guérin(5), Kenneth W. Culver(5), David H. Collier(4), Hema N. Viswanathan(4), Ajay Nirula(4), Anthony Wang(4), Julie Blædel(4), Zheng‐Yi Zhou(3), Marie Louise Ricculli(3), Rishi Desai(3), Mufaddal Mahesri(3), Denise Globe(3), Rhonda L. Bohn(3), Maureen Achebe(3), Raisa Levin(3), Sebastian Schneeweiß(3), Philip J. Mease(3), Mark C. Genovese(3)